Exelixis
EXEL
#1855
Rank
A$15.98 B
Marketcap
A$59.39
Share price
-2.18%
Change (1 day)
12.09%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

P/E ratio for Exelixis (EXEL)

P/E ratio as of January 2026 (TTM): 17.5

According to Exelixis's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 17.4601. At the end of 2023 the company had a P/E ratio of 36.7.

P/E ratio history for Exelixis from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202336.730.49%
202228.113.92%
202124.7-54.46%
202054.2226.32%
201916.694.37%
20188.55-85.09%
201757.4-226.95%
2016-45.2540.88%
2015-7.05580.52%
2014-1.04-77.69%
2013-4.64

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
21.8 25.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
15.3-12.40%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
26.2 49.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
12.6-27.73%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
14.5-16.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
18.4 5.46%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
14.3-17.99%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-0.2411-101.38%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-17.9-202.27%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.